CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

GLP-1 medications such as Ozempic and Wegovy have had a transformative effect for those struggling with weight loss. Many ...

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

GLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...